LNK01004 ointment 0.3%

DRUG2 trials

Sponsors

Lynk Pharmaceuticals Co., Ltd

Conditions

Atopic Dermatitis

Phase 1

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

CompletedNCT06553287

Lynk Pharmaceuticals Co., LtdAtopic Dermatitis

Start: 2023-07-12End: 2024-06-18Updated: 2024-08-14

Phase 2

A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis

CompletedNCT07071610

Lynk Pharmaceuticals Co., LtdAtopic Dermatitis

Start: 2025-03-18End: 2025-07-24Updated: 2026-01-14